Melatonergic Sleep Promotion: Fundamental Chronobiological Issues Concerning Sleep Onset and Maintenance, Dose and Duration of Action

2017 ◽  
Vol 2 (1) ◽  
pp. 5-11
Author(s):  
Rüdiger Hardeland
Diseases ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 18
Author(s):  
Rüdiger Hardeland

Melatonin has been used preclinically and clinically for different purposes. Some applications are related to readjustment of circadian oscillators, others use doses that exceed the saturation of melatonin receptors MT1 and MT2 and are unsuitable for chronobiological purposes. Conditions are outlined for appropriately applying melatonin as a chronobiotic or for protective actions at elevated levels. Circadian readjustments require doses in the lower mg range, according to receptor affinities. However, this needs consideration of the phase response curve, which contains a silent zone, a delay part, a transition point and an advance part. Notably, the dim light melatonin onset (DLMO) is found in the silent zone. In this specific phase, melatonin can induce sleep onset, but does not shift the circadian master clock. Although sleep onset is also under circadian control, sleep and circadian susceptibility are dissociated at this point. Other limits of soporific effects concern dose, duration of action and poor individual responses. The use of high melatonin doses, up to several hundred mg, for purposes of antioxidative and anti-inflammatory protection, especially in sepsis and viral diseases, have to be seen in the context of melatonin’s tissue levels, its formation in mitochondria, and detoxification of free radicals.


2000 ◽  
Vol 14 (3) ◽  
pp. 151-158 ◽  
Author(s):  
José Luis Cantero ◽  
Mercedes Atienza

Abstract High-resolution frequency methods were used to describe the spectral and topographic microstructure of human spontaneous alpha activity in the drowsiness (DR) period at sleep onset and during REM sleep. Electroencephalographic (EEG), electrooculographic (EOG), and electromyographic (EMG) measurements were obtained during sleep in 10 healthy volunteer subjects. Spectral microstructure of alpha activity during DR showed a significant maximum power with respect to REM-alpha bursts for the components in the 9.7-10.9 Hz range, whereas REM-alpha bursts reached their maximum statistical differentiation from the sleep onset alpha activity at the components between 7.8 and 8.6 Hz. Furthermore, the maximum energy over occipital regions appeared in a different spectral component in each brain activation state, namely, 10.1 Hz in drowsiness and 8.6 Hz in REM sleep. These results provide quantitative information for differentiating the drowsiness alpha activity and REM-alpha by studying their microstructural properties. On the other hand, these data suggest that the spectral microstructure of alpha activity during sleep onset and REM sleep could be a useful index to implement in automatic classification algorithms in order to improve the differentiation between the two brain states.


2017 ◽  
Vol 36 (06) ◽  
pp. 435-438
Author(s):  
M. Sparmann ◽  
D. Müller
Keyword(s):  

ZusammenfassungUnter Bezugnahme auf einen Fallbericht mit stromstoßartigen Empfindungen im Rachen beim Einschlafen sowie Zusammenzucken infolge Erschreckens dabei und unabhängig davon Zuckungen der Arme oder Beine sowie Apnoen wird auf das Vorkommen von sensiblen oder sensorischen Wahrnehmungen als ungewöhnliche Begleiterscheinungen von Einschlafmyoklonien hingewiesen. Sie können auch ohne Zuckungen als deren Äquivalente bzw. Varianten auftreten und werden sensory sleep starts genannt. Bislang hat das Gefühl des explodierenden Kopfes besondere Beachtung gefunden und ist in der internationalen Klassifikation der Schlafstörungen als exploding head syndrome neben den Halluzinationen angeführt, obgleich es zu diesen gehört.


1996 ◽  
Vol 75 (05) ◽  
pp. 731-733 ◽  
Author(s):  
V Cazaux ◽  
B Gauthier ◽  
A Elias ◽  
D Lefebvre ◽  
J Tredez ◽  
...  

SummaryDue to large inter-individual variations, the dose of vitamin K antagonist required to target the desired hypocoagulability is hardly predictible for a given patient, and the time needed to reach therapeutic equilibrium may be excessively long. This work reports on a simple method for predicting the daily maintenance dose of fluindione after the third intake. In a first step, 37 patients were delivered 20 mg of fluindione once a day, at 6 p.m. for 3 consecutive days. On the morning of the 4th day an INR was performed. During the following days the dose was adjusted to target an INR between 2 and 3. There was a good correlation (r = 0.83, p<0.001) between the INR performed on the morning of day 4 and the daily maintenance dose determined later by successive approximations. This allowed us to write a decisional algorithm to predict the effective maintenance dose of fluindione from the INR performed on day 4. The usefulness and the safety of this approach was tested in a second prospective study on 46 patients receiving fluindione according to the same initial scheme. The predicted dose was compared to the effective dose soon after having reached the equilibrium, then 30 and 90 days after. To within 5 mg (one quarter of a tablet), the predicted dose was the effective dose in 98%, 86% and 81% of the patients at the 3 times respectively. The mean time needed to reach the therapeutic equilibrium was reduced from 13 days in the first study to 6 days in the second study. No hemorrhagic complication occurred. Thus the strategy formerly developed to predict the daily maintenance dose of warfarin from the prothrombin time ratio or the thrombotest performed 3 days after starting the treatment may also be applied to fluindione and the INR measurement.


1982 ◽  
Vol 47 (03) ◽  
pp. 230-231 ◽  
Author(s):  
N K Sharma ◽  
P A Routledge ◽  
M D Rawlins ◽  
D M Davies

SummaryThe validity of a previously described technique for predicting warfarin requirements based on the anticoagulant response to a fixed loading dose was assessed prospectively in 57 patients. There was a close relationship between the predicted and initially observed daily warfarin dose required to maintain the patient within the therapeutic range for anticoagulation. The significant relationship between predicted and observed maintenance dose persisted at 4 and 12 weeks although it decreased with increasing time.The relationship between observed and predicted maintenance requirement of warfarin was not affected by the concomitant use of intermittent intravenous injections of heparin when 9 hr was allowed to elapse between the previous dose of heparin and the thrombotest estimation on which the prediction was based.It is concluded that the method is valuable in predicting an individual’s warfarin requirement, although it does not obviate the need for regular monitoring of anticoagulant control.


1969 ◽  
Vol 61 (1_Suppl) ◽  
pp. S108
Author(s):  
Jan L. Mulder ◽  
Olof de Maré ◽  
Per Axel Heedman
Keyword(s):  

ORL ro ◽  
2016 ◽  
Vol 4 (1) ◽  
pp. 56-59
Author(s):  
Raluca Ioana Teleanu ◽  
Magdalena Sandu ◽  
Eugenia Roza

Melatonin  is a hormone produced by the pineal gland during the night, as a response to the light-darkness variation. The endogenous melatonin levels have a cyclic evolution throughout the entire life. Various roles have been cited such as the in utero developement of the fetus through its action on the placenta, neurons and glial cells, a major role in the regulation of the cyrcadian rhythm, antioxidative, antiinflammatory roles, as well as celullar and umoral immunity modulation. In the European Union, exogenous melatonin has been evaluated by the European Food Safety Authority (EFSA) for reducing sleep onset latency and the conclusion was that it has efficacy studies in this regard.  


2020 ◽  
Vol 27 (25) ◽  
pp. 4157-4164 ◽  
Author(s):  
Taku Fukuzawa ◽  
Junichi Nezu

Background: The complement system usually helps protect against microbial infection, but it could also be involved in the onset of various diseases. Inhibition of complement component 5 (C5) with eculizumab has resulted in a significant reduction of hemolysis, reduction of thromboembolic events, and increased survival in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). However, eculizumab requires frequent intravenous infusions due to the abundance of C5 in plasma and some patients may still experience breakthrough hemolysis. This review introduces the recent body of knowledge on recycling technology and discusses the likely therapeutic benefits of SKY59, a novel recycling antibody, for PNH and complement-mediated disorders. Methods: By using recycling technology, we created a novel anti-C5 antibody, SKY59, capable of binding to C5 pH-dependently. Results: In cynomolgus monkeys, SKY59 robustly inhibited C5 and complement activity for significantly longer than a conventional antibody. SKY59 also showed an inhibitory effect on C5 variant p.Arg885His, whereas eculizumab does not suppress complement activity in patients with this type of mutation. Conclusion: SKY59 is a promising anti-C5 biologic agent that has significant advantages over current therapies such as long duration of action and efficacy against C5 variants.


Sign in / Sign up

Export Citation Format

Share Document